RespireRx Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
RSPI RespireRx Pharmaceuticals Inc
AIN Albany International Corp
BTVRF BlueRush Inc
GOLF Acushnet Holdings Corp
AA Alcoa Corp
CNCE Concert Pharmaceuticals Inc
BL Blackline Inc
DFEN Direxion Daily Aerospace & Defense Bull 3X Shares Direxion Daily Aerospace
NVRO Nevro Corp
DBI Designer Brands Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

RespireRx Pharmaceuticals Inc. is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is developing treatment options that address obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD) epilepsy, chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect people. Its pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the nervous system’s endogenous cannabinoid receptors. Its neuromodulators platform consists of two programs: its AMPAkines program, which includes compounds that are positive allosteric modulators (PAMs) of AMPA-type glutamate receptors to promote neuronal function and GABAkines program, including compounds that are PAMs of GABAA receptors.

The symbol you entered, COR, changed to RSPI.

Closing Price
$0.017
Day's Change
0.003 (21.43%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0176
Day's Low
0.0166
Volume
(Heavy Day)
Volume:
151,324

10-day average volume:
56,417
151,324

Company Profile

RespireRx Pharmaceuticals Inc. is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is developing treatment options that address obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD) epilepsy, chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect people. Its pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the nervous system’s endogenous cannabinoid receptors. Its neuromodulators platform consists of two programs: its AMPAkines program, which includes compounds that are positive allosteric modulators (PAMs) of AMPA-type glutamate receptors to promote neuronal function and GABAkines program, including compounds that are PAMs of GABAA receptors.

Valuation Ratios

No valuation ratios available.

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

No short interest available.

Share Information

RSPI is in a share class of common stock
Float
68.0M
Shares Outstanding
94.9M
Institutions Holding Shares
--
--

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Arnold S. LippaChmn.
  • Timothy L. JonesPres.
  • Jeff E. MargolisCFO
  • David DickasonSr.VP
  • Richard PurcellSr.VP

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.